0001209191-15-024177.txt : 20150309
0001209191-15-024177.hdr.sgml : 20150309
20150309173411
ACCESSION NUMBER: 0001209191-15-024177
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150129
FILED AS OF DATE: 20150309
DATE AS OF CHANGE: 20150309
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INFINITY PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001113148
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330655706
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6174531000
MAIL ADDRESS:
STREET 1: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: INFINITY PHARMACEUTICALS, INC./NEW/
DATE OF NAME CHANGE: 20060913
FORMER COMPANY:
FORMER CONFORMED NAME: DISCOVERY PARTNERS INTERNATIONAL INC
DATE OF NAME CHANGE: 20000428
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Perkins Adelene Q
CENTRAL INDEX KEY: 0001375124
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-31141
FILM NUMBER: 15686307
MAIL ADDRESS:
STREET 1: C/O INFINITY PHARMACEUTICALS, INC.
STREET 2: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2015-01-29
2015-02-02
1
0001113148
INFINITY PHARMACEUTICALS, INC.
INFI
0001375124
Perkins Adelene Q
C/O INFINITY PHARMACEUTICALS, INC.
780 MEMORIAL DRIVE
CAMBRIDGE
MA
02139
1
1
0
0
President & CEO
Common Stock
2015-01-29
4
S
0
20000
14.8268
D
429432
D
The disposition reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 26, 2014.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.50 to $15.13, inclusive. The reporting person undertakes to provide to Infinity Pharmaceuticals, Inc., any security holder of Infinity Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2.
This amendment is being filed to correct the total amount of securities beneficially owned following the reported transaction. Includes 930 and 967 shares of common stock purchased through participation in the issuer's Employee Stock Purchase Plan on June 30, 2014 and December 31, 2014, respectively.
/s/ Adelene Q. Perkins
2015-03-06